RecruitingNCT06566716

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass

Validation of Ovarian Adnexal Mass Assessment Score Test System

Sponsor

Cleo Diagnostics Ltd

Enrollment

1,000 participants

Start Date

Sep 6, 2024

Study Type

OBSERVATIONAL

Conditions

Ovarian Neoplasms

Summary

Ovarian cancer is a serious health risk with the highest death rate among gynecological cancers. Unfortunately, it's only possible to definitively diagnose ovarian cancer after surgery, as there are no reliable tests to determine if an ovarian abnormality is cancerous or benign before surgery. Cleo Diagnostics have developed a new test that uses five biomarkers in the blood to better differentiate between benign and malignant ovarian conditions. In initial studies, this test outperformed the current standard test, CA125, in identifying cancer. This study aims to evaluate the effectiveness of the Cleo Diagnostics (CleoDX) Ovarian Adnexal Mass Score Test System. This test measures five analytes in the blood and provides a score indicating the likelihood of cancer in patients with an adnexal mass requiring surgery. The test is designed to assist doctors in making better-informed decisions about surgery and patient care by providing a more accurate pre-surgical assessment of cancer risk. By doing so, it aims to improve patient outcomes and ensure that those with malignant conditions receive the appropriate specialist care.

Eligibility

Sex: FEMALEMin Age: 18 Years

Inclusion Criteria3

female patients =\> 18 years of age at the time of consent
Can provide written informed consent
Have an ovarian cyst or adnexal mass (simple, complex, or solid ovarian/pelvic mass) identified through imaging examination (e.g. transvaginal ultrasound - TVU) that requires surgery, but have not yet undergone this surgery

Exclusion Criteria7

Any prior confirmed diagnosis of, or treatment for, ovarian cancer
Any prior surgery resulting in removal of both ovaries
Prior history of gynecological malignancy (within last 2 years)
Prior history of melanoma (within last 2 years)
Prior treatment (within 12 months of sample collection) with chemotherapy, radiotherapy or immunotherapy
Immune-compromised. Definition: those whose weakened immune system may render them more susceptible to infection, illness, or complications. These may include patients with immune-suppressive conditions (e.g. HIV/AIDS), patients undergoing immuno-, chemo- or radio-therapy (within the last 12 months) for any reason, receiving immune suppressive therapies (e.g. transplant recipients, individuals with known autoimmune disease), or with a primary immunodeficiency disorder (e.g. Lupus).
Pregnant currently or within the last 3 months based on participant self-report